165 related articles for article (PubMed ID: 24336157)
1. Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma.
Milea A; George SH; Matevski D; Jiang H; Madunic M; Berman HK; Gauthier ML; Gallie B; Shaw PA
Mod Pathol; 2014 Jul; 27(7):991-1001. PubMed ID: 24336157
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of Rb1, P16 and ER as diagnostic, prognostic and potential targets for therapeutic agents in ovarian epithelial tumors: an immunohistochemical study of 130 ovarian carcinomas.
Ferguson DC; Long DJ; Smith MC; Craig-Owens LD; Means J; Fadare O; Desouki MM
J Ovarian Res; 2015 Jun; 8():34. PubMed ID: 26043844
[TBL] [Abstract][Full Text] [Related]
3. Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein.
Armes JE; Lourie R; de Silva M; Stamaratis G; Boyd A; Kumar B; Price G; Hyde S; Allen D; Grant P; Venter DJ
Int J Gynecol Pathol; 2005 Oct; 24(4):363-8. PubMed ID: 16175083
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic alterations in Rb pathway have more prognostic influence than p53 pathway proteins in oral carcinoma.
Jayasurya R; Sathyan KM; Lakshminarayanan K; Abraham T; Nalinakumari KR; Abraham EK; Nair MK; Kannan S
Mod Pathol; 2005 Aug; 18(8):1056-66. PubMed ID: 15731778
[TBL] [Abstract][Full Text] [Related]
5. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.
Rambau PF; Vierkant RA; Intermaggio MP; Kelemen LE; Goodman MT; Herpel E; Pharoah PD; Kommoss S; Jimenez-Linan M; Karlan BY; Gentry-Maharaj A; Menon U; Polo SH; Candido Dos Reis FJ; Doherty JA; Gayther SA; Sharma R; Larson MC; Harnett PR; Hatfield E; de Andrade JM; Nelson GS; Steed H; Schildkraut JM; Carney ME; Høgdall E; Whittemore AS; Widschwendter M; Kennedy CJ; Wang F; Wang Q; Wang C; Armasu SM; Daley F; Coulson P; Jones ME; Anglesio MS; Chow C; de Fazio A; García-Closas M; Brucker SY; Cybulski C; Harris HR; Hartkopf AD; Huzarski T; Jensen A; Lubiński J; Oszurek O; Benitez J; Mina F; Staebler A; Taran FA; Pasternak J; Talhouk A; Rossing MA; Hendley J; ; Edwards RP; Fereday S; Modugno F; Ness RB; Sieh W; El-Bahrawy MA; Winham SJ; Lester J; Kjaer SK; Gronwald J; Sinn P; Fasching PA; Chang-Claude J; Moysich KB; Bowtell DD; Hernandez BY; Luk H; Behrens S; Shah M; Jung A; Ghatage P; Alsop J; Alsop K; García-Donas J; Thompson PJ; Swerdlow AJ; Karpinskyj C; Cazorla-Jiménez A; García MJ; Deen S; Wilkens LR; Palacios J; Berchuck A; Koziak JM; Brenton JD; Cook LS; Goode EL; Huntsman DG; Ramus SJ; Köbel M
J Pathol Clin Res; 2018 Oct; 4(4):250-261. PubMed ID: 30062862
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of Apaf-1, Cyclin D1, and AQP-5 in serous ovarian carcinoma treated with the first-line chemotherapy.
Abdelrahman AE; Fathy A; Elsebai EA; Nawar N; Etman WM
Ann Diagn Pathol; 2018 Aug; 35():27-37. PubMed ID: 30072015
[TBL] [Abstract][Full Text] [Related]
7. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
[TBL] [Abstract][Full Text] [Related]
8. Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.
Garsed DW; Alsop K; Fereday S; Emmanuel C; Kennedy CJ; Etemadmoghadam D; Gao B; Gebski V; Garès V; Christie EL; Wouters MCA; Milne K; George J; Patch AM; Li J; Arnau GM; Semple T; Gadipally SR; Chiew YE; Hendley J; Mikeska T; Zapparoli GV; Amarasinghe K; Grimmond SM; Pearson JV; Waddell N; Hung J; Stewart CJR; Sharma R; Allan PE; Rambau PF; McNally O; Mileshkin L; Hamilton A; Ananda S; Grossi M; Cohen PA; Leung YC; Rome RM; Beale P; Blomfield P; Friedlander M; Brand A; Dobrovic A; Köbel M; Harnett P; Nelson BH; Bowtell DDL; deFazio A;
Clin Cancer Res; 2018 Feb; 24(3):569-580. PubMed ID: 29061645
[No Abstract] [Full Text] [Related]
9. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
Bali A; O'Brien PM; Edwards LS; Sutherland RL; Hacker NF; Henshall SM
Clin Cancer Res; 2004 Aug; 10(15):5168-77. PubMed ID: 15297421
[TBL] [Abstract][Full Text] [Related]
10. Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma.
Krämer A; Schultheis B; Bergmann J; Willer A; Hegenbart U; Ho AD; Goldschmidt H; Hehlmann R
Leukemia; 2002 Sep; 16(9):1844-51. PubMed ID: 12200702
[TBL] [Abstract][Full Text] [Related]
11. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.
Karst AM; Jones PM; Vena N; Ligon AH; Liu JF; Hirsch MS; Etemadmoghadam D; Bowtell DD; Drapkin R
Cancer Res; 2014 Feb; 74(4):1141-52. PubMed ID: 24366882
[TBL] [Abstract][Full Text] [Related]
12. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.
Edamoto Y; Hara A; Biernat W; Terracciano L; Cathomas G; Riehle HM; Matsuda M; Fujii H; Scoazec JY; Ohgaki H
Int J Cancer; 2003 Sep; 106(3):334-41. PubMed ID: 12845670
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
14. CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma.
Kuhn E; Wang TL; Doberstein K; Bahadirli-Talbott A; Ayhan A; Sehdev AS; Drapkin R; Kurman RJ; Shih IeM
Mod Pathol; 2016 Oct; 29(10):1254-61. PubMed ID: 27443516
[TBL] [Abstract][Full Text] [Related]
15. Analysis of p53, p16(INK4a), pRb and Cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas.
Bilyk OO; Pande NT; Buchynska LG
Exp Oncol; 2011 Sep; 33(3):150-6. PubMed ID: 21956468
[TBL] [Abstract][Full Text] [Related]
16. Critical molecular abnormalities in high-grade serous carcinoma of the ovary.
Köbel M; Huntsman D; Gilks CB
Expert Rev Mol Med; 2008 Aug; 10():e22. PubMed ID: 18671886
[TBL] [Abstract][Full Text] [Related]
17. Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis.
Güner D; Sturm I; Hemmati P; Hermann S; Hauptmann S; Wurm R; Budach V; Dörken B; Lorenz M; Daniel PT
Int J Cancer; 2003 Feb; 103(4):445-54. PubMed ID: 12478659
[TBL] [Abstract][Full Text] [Related]
18. Durable response to palbociclib and letrozole in ovarian cancer with
Frisone D; Charrier M; Clement S; Christinat Y; Thouvenin L; Homicsko K; Michielin O; Bodmer A; Chappuis PO; McKee TA; Tsantoulis P
Cancer Biol Ther; 2020; 21(3):197-202. PubMed ID: 31709901
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
[TBL] [Abstract][Full Text] [Related]
20. Abnormal expression of p16(INK4a), cyclin D1, cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas.
Kishimoto I; Mitomi H; Ohkura Y; Kanazawa H; Fukui N; Watanabe M
J Surg Oncol; 2008 Jul; 98(1):60-6. PubMed ID: 18484097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
